tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

BRNS Stock Latest News

Barinthus Biotherapeutics Reports Promising IM-PROVE II Trial Results
Company AnnouncementsBarinthus Biotherapeutics Reports Promising IM-PROVE II Trial Results
8d ago
8K
BRNS
Barinthus announces results from ongoing Phase 2b HBV003 trial
PremiumThe Fly
Barinthus announces results from ongoing Phase 2b HBV003 trial
8d ago
BRNS
Arbutus and Barinthus announce new data from IM-PROVE II trial
PremiumThe Fly
Arbutus and Barinthus announce new data from IM-PROVE II trial
8d ago
ABUS
BRNS
JMP Securities healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
JMP Securities healthcare analysts hold an analyst/industry conference call
12d ago
GSK
VIR
Barinthus Biotherapeutics reports Q3 EPS (21c), consensus (44c)
PremiumThe Fly
Barinthus Biotherapeutics reports Q3 EPS (21c), consensus (44c)
17d ago
BRNS
JMP Securities healthcare analysts hold an analyst/industry conference call
PremiumThe FlyJMP Securities healthcare analysts hold an analyst/industry conference call
1M ago
GSK
VIR
Barinthus Bio completes enrollment for hepatitis B, prostate cancer trials
Premium
The Fly
Barinthus Bio completes enrollment for hepatitis B, prostate cancer trials
2M ago
BRNS
Barinthus Biotherapeutics initiates Phase 1 clinical trial of VTP-1000
Premium
The Fly
Barinthus Biotherapeutics initiates Phase 1 clinical trial of VTP-1000
2M ago
BRNS
Barinthus Biotherapeutics Elevates Griffiths to COO
PremiumCompany Announcements
Barinthus Biotherapeutics Elevates Griffiths to COO
3M ago
8K
BRNS
Barinthus price target lowered to $9.50 from $11 at Alliance Global Partners
PremiumThe Fly
Barinthus price target lowered to $9.50 from $11 at Alliance Global Partners
3M ago
BRNS
Barinthus Biotherapeutics reports Q2 EPS (43c), consensus (41c)
PremiumThe Fly
Barinthus Biotherapeutics reports Q2 EPS (43c), consensus (41c)
4M ago
BRNS
Barinthus Biotherapeutics price target lowered to $5 from $8 at H.C. Wainwright
PremiumThe Fly
Barinthus Biotherapeutics price target lowered to $5 from $8 at H.C. Wainwright
5M ago
BRNS
Barinthus Biotherapeutics price target lowered to $3 from $7 at Barclays
PremiumThe FlyBarinthus Biotherapeutics price target lowered to $3 from $7 at Barclays
5M ago
BRNS
Barinthus Biotherapeutics to prioritize VTP-300, reduce workforce by 25%
Premium
The Fly
Barinthus Biotherapeutics to prioritize VTP-300, reduce workforce by 25%
5M ago
BRNS
Barinthus Biotherapeutics Breakthrough in Hepatitis B Treatment
Premium
Company Announcements
Barinthus Biotherapeutics Breakthrough in Hepatitis B Treatment
6M ago
8K
BRNS
Barinthus presents EOT data from Phase 2a trial of imdusiran, VTP-300
PremiumThe Fly
Barinthus presents EOT data from Phase 2a trial of imdusiran, VTP-300
6M ago
ABUS
BRNS
Arbutus announces preliminary EOT data from Phase 2a trial of imdusiran, VTP-300
PremiumThe Fly
Arbutus announces preliminary EOT data from Phase 2a trial of imdusiran, VTP-300
6M ago
ABUS
BRNS
Barinthus Biotherapeutics to present VTP-300 data updates at EASL Congress 2024
PremiumThe Fly
Barinthus Biotherapeutics to present VTP-300 data updates at EASL Congress 2024
6M ago
BRNS
Barinthus price target lowered to $11 from $12 at Alliance Global Partners
PremiumThe Fly
Barinthus price target lowered to $11 from $12 at Alliance Global Partners
6M ago
BRNS
Barinthus Biotherapeutics sees cash runway into 4Q25
PremiumThe FlyBarinthus Biotherapeutics sees cash runway into 4Q25
6M ago
BRNS
Barinthus Biotherapeutics reports Q1 EPS (40c), consensus (54c)
Premium
The Fly
Barinthus Biotherapeutics reports Q1 EPS (40c), consensus (54c)
6M ago
BRNS
Barinthus Biotherapeutics appoints Hooftman as Chief Medical Officer
Premium
The Fly
Barinthus Biotherapeutics appoints Hooftman as Chief Medical Officer
7M ago
BRNS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >